PET with F-18 flortaucipir showed increased uptake in the medial and inferior temporal lobes of individuals with subcortical vascular cognitive impairment, with both cerebral small vessel disease and beta-amyloid independently tied to higher flortaucipir uptake, compared with healthy controls, researchers reported in JAMA Neurology. Another study in the same journal using PET with F-18 flutemetamol found that individuals with positive PET scans at baseline were 2.5 times more likely to develop Alzheimer's disease within three years, while those with positive PET scans and low hippocampal volume had a 5.6 times higher likelihood of developing the disease, compared with those with negative PET results.
PET radiotracers show promise in predicting Alzheimer's risk
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.